litifilimab   Click here for help

GtoPdb Ligand ID: 11122

Synonyms: BIIB-059 | BIIB059
Immunopharmacology Ligand
Compound class: Antibody
Comment: Litifilimab (BIIB059) is a fully humanized IgG1, CLEC4C (blood dendritic cell antigen 2, BDCA2) targeting monoclonal antibody. It is being evaluated for ability to reduce release of disease-driving interferons (principally IFN-α) in SLE/CLE. BIIB059 was developed by Biogen, based on prior evidence of target engagement and SLE-applicable immunomodulatory efficacy of a humanized mAb against BDCA2 named 24F4A [3].
1. Furie R, Werth VP, Merola JF, Stevenson L, Reynolds TL, Naik H, Wang W, Christmann R, Gardet A, Pellerin A et al.. (2019)
Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus.
J Clin Invest, 129 (3): 1359-1371. [PMID:30645203]
2. Furie RA, van Vollenhoven RF, Kalunian K, Navarra S, Romero-Diaz J, Werth VP, Huang X, Clark G, Carroll H, Meyers A et al.. (2022)
Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.
N Engl J Med, 387 (10): 894-904. [PMID:36069871]
3. Pellerin A, Otero K, Czerkowicz JM, Kerns HM, Shapiro RI, Ranger AM, Otipoby KL, Taylor FR, Cameron TO, Viney JL et al.. (2015)
Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms.
EMBO Mol Med, 7 (4): 464-76. [PMID:25762615]
4. Werth VP, Furie RA, Romero-Diaz J, Navarra S, Kalunian K, van Vollenhoven RF, Nyberg F, Kaffenberger BH, Sheikh SZ, Radunovic G et al.. (2022)
Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.
N Engl J Med, 387 (4): 321-331. [PMID:35939578]